An Open-Label, Single-Sequence Study to Investigate the Effects of Cyclosporine on the Pharmacokinetics of BMS-986165 at Steady State in Healthy Male Participants.

Trial Profile

An Open-Label, Single-Sequence Study to Investigate the Effects of Cyclosporine on the Pharmacokinetics of BMS-986165 at Steady State in Healthy Male Participants.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs BMS 986165 (Primary) ; Ciclosporin
  • Indications Autoimmune disorders; Inflammatory bowel diseases; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top